Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. — VialBase Research

Summary

This preclinical follow-up study examined the cecal microbiome of diet-induced obese (DIO) mice treated with a nicotinamide N-methyltransferase inhibitor (NNMTi), identified explicitly in the paper as 5-amino-1-methylquinolinium, in combination with a low-fat diet (LD). The premise came from prior work in which NNMTi combined with LD promoted dramatic whole-body adiposity and weight loss and rapidly normalized these measures to age-matched lean animals, while an LD switch alone could not restore them in the same time frame. Because mouse microbiome profiles often correlate strongly with body weight and fat composition, the authors asked whether the microbiomes of NNMTi plus LD mice resembled age-matched lean counterparts and differed from DIO mice kept on a high-fat Western diet (WD) or switched to LD alone. There were minimal microbiome differences between lean and obese controls, implying that diet composition and adiposity by themselves had limited effect; however, DIO mice switched from WD to LD — regardless of treatment status — showed several genus- and phylum-level differences versus both obese and lean controls. Alpha diversity measures did not differ significantly between groups, while beta diversity principal coordinates analysis indicated that mice within the same treatment group were most similar to each other. K-means clustering of amplicon sequence variants by animal showed that NNMTi-treated DIO mice switched to LD had a distinct microbiome pattern marked by decreased Erysipelatoclostridium and increased Lactobacillus relative abundance compared with vehicle counterparts, genera the authors note are tied to body weight and metabolic regulation. Parasutterella relative abundance, elevated in both vehicle- and NNMTi-treated LD-switched groups relative to controls, significantly correlated with several adipose tissue metabolite abundances. The authors describe the results as a novel foundation for future investigations rather than a definitive mechanism.

Key Findings

• All data are from mice (diet-induced obese model); the study reports cecal microbiome profiling, not human outcomes
• The NNMT inhibitor is named explicitly as 5-amino-1-methylquinolinium and was administered combined with a low-fat diet switch, with LD-switch-alone and diet controls as comparators
• Minimal microbiome differences between lean and obese controls suggested diet composition and adiposity on their own had limited microbiome effect; alpha diversity did not significantly differ between groups
• Beta diversity principal coordinates analysis showed mice from the same treatment group clustered most closely, and k-means clustering identified a distinct microbiome pattern in the NNMTi + LD group
• The distinguishing signature was decreased Erysipelatoclostridium and increased Lactobacillus relative abundance versus vehicle; Parasutterella, elevated in both LD-switched groups, significantly correlated with several adipose tissue metabolite abundances

Relevance to 5-Amino-1MQ

This is the paper that ties the NNMT inhibitor literature most directly to 5-Amino-1MQ by name, since it identifies the test compound as 5-amino-1-methylquinolinium rather than a generic NNMTi. That makes it useful for establishing that the widely sold compound is the same molecule studied in the obesity literature — but the study itself is again preclinical, conducted in DIO mice, and again tests the compound combined with a reduced-calorie/low-fat diet switch rather than as a standalone intervention. Its actual findings are exploratory microbiome associations, and the authors themselves frame the work as a foundation for future investigation, not as evidence of a therapeutic mechanism. It should not be used to claim that 5-amino-1MQ improves the human gut microbiome or that microbiome shifts explain any human fat-loss effect, because no such human data exist.

Citation

Dimet-Wiley A, Wu Q, Wiley JT, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific reports. 2022;12(1):484. doi:10.1038/s41598-021-03670-5.

See Also

• Parent compound: 5-Amino-1MQ